Spectaire (SPEC) Competitors $0.0003 0.00 (0.00%) As of 09/17/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock SPEC vs. TBIO, THMO, HTGMQ, OLITW, PRENW, QSIAW, SMAPW, TT, KEYS, and VLTOShould you be buying Spectaire stock or one of its competitors? The main competitors of Spectaire include Telesis Bio (TBIO), ThermoGenesis (THMO), HTG Molecular Diagnostics (HTGMQ), OmniLit Acquisition (OLITW), Prenetics Global (PRENW), Quantum-Si (QSIAW), SportsMap Tech Acquisition (SMAPW), Trane Technologies (TT), Keysight Technologies (KEYS), and Veralto (VLTO). These companies are all part of the "measuring and control equipment" industry. Spectaire vs. Its Competitors Telesis Bio ThermoGenesis HTG Molecular Diagnostics OmniLit Acquisition Prenetics Global Quantum-Si SportsMap Tech Acquisition Trane Technologies Keysight Technologies Veralto Spectaire (NASDAQ:SPEC) and Telesis Bio (NASDAQ:TBIO) are both small-cap measuring and control equipment companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, media sentiment, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk. Do institutionals & insiders have more ownership in SPEC or TBIO? 26.5% of Spectaire shares are owned by institutional investors. Comparatively, 37.6% of Telesis Bio shares are owned by institutional investors. 25.4% of Spectaire shares are owned by insiders. Comparatively, 24.5% of Telesis Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Which has better valuation & earnings, SPEC or TBIO? Spectaire has higher earnings, but lower revenue than Telesis Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpectaireN/AN/A$8.95MN/AN/ATelesis Bio$225.09M0.00-$47.72M-$28.200.00 Does the media favor SPEC or TBIO? In the previous week, Spectaire's average media sentiment score of 0.00 beat Telesis Bio's score of -1.00 indicating that Spectaire is being referred to more favorably in the media. Company Overall Sentiment Spectaire Neutral Telesis Bio Negative Is SPEC or TBIO more profitable? Spectaire has a net margin of 0.00% compared to Telesis Bio's net margin of -336.59%. Telesis Bio's return on equity of 0.00% beat Spectaire's return on equity.Company Net Margins Return on Equity Return on Assets SpectaireN/A -81.22% 304.57% Telesis Bio -336.59%N/A -61.89% Which has more risk & volatility, SPEC or TBIO? Spectaire has a beta of -6.38, suggesting that its share price is 738% less volatile than the S&P 500. Comparatively, Telesis Bio has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500. SummarySpectaire beats Telesis Bio on 5 of the 9 factors compared between the two stocks. Get Spectaire News Delivered to You Automatically Sign up to receive the latest news and ratings for SPEC and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPEC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart SPEC vs. The Competition Export to ExcelMetricSpectaireMeasuring & controlling devices IndustryComputer SectorNASDAQ ExchangeMarket Cap$6K$33.23M$31.83B$10.28BDividend YieldN/A8.77%3.16%4.64%P/E RatioN/A3.87452.0926.97Price / SalesN/A3.191,907.37128.91Price / CashN/A8.3837.2060.63Price / Book0.001.657.536.37Net Income$8.95M$7.16M$809.77M$271.46M7 Day PerformanceN/A-3.00%3.94%2.53%1 Month PerformanceN/A4.71%9.10%9.42%1 Year PerformanceN/A-15.09%24,200.34%30.16% Spectaire Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPECSpectaireN/A$0.00flatN/AN/A$6KN/A0.008TBIOTelesis Bio0.3048 of 5 stars$0.01flatN/A-99.9%$22K$225.09M0.00200Short Interest ↑THMOThermoGenesisN/AN/AN/AN/A$1K$9.61M0.0040HTGMQHTG Molecular DiagnosticsN/AN/AN/A-50.0%$0.00$6.37M0.0090OLITWOmniLit AcquisitionN/A$0.07+4.8%N/A+40.4%$0.00N/A0.003Gap UpPRENWPrenetics GlobalN/A$0.03+11.2%N/A+114.7%$0.00$41.52M0.001Positive NewsGap DownQSIAWQuantum-SiN/A$0.25+16.2%N/A+241.4%$0.00$3.41M0.00150Positive NewsShort Interest ↑Gap UpSMAPWSportsMap Tech AcquisitionN/A$0.03-2.6%N/A-27.5%$0.00N/A0.00N/AGap DownTTTrane Technologies4.7297 of 5 stars$417.12+1.9%$458.60+9.9%+8.4%$91.10B$19.84B33.0845,000Positive NewsAnalyst ForecastHigh Trading VolumeKEYSKeysight Technologies4.4176 of 5 stars$170.26+0.7%$187.38+10.1%+18.0%$29.06B$4.98B54.2215,500Positive NewsAnalyst RevisionVLTOVeralto3.3006 of 5 stars$106.00+0.9%$113.43+7.0%-0.9%$26.06B$5.19B29.6117,000Positive NewsDividend Announcement Related Companies and Tools Related Companies TBIO Alternatives THMO Alternatives HTGMQ Alternatives OLITW Alternatives PRENW Alternatives QSIAW Alternatives SMAPW Alternatives TT Alternatives KEYS Alternatives VLTO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPEC) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectaire Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spectaire With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
